Blog

XenoPort's psoriasis drug shows higher side effects; shares fall

XenoPort Inc’s psoriasis drug showed high rates of gastrointestinal-related side effects, overshadowing its success in a mid-stage study. XenoPort should stop spending limited resources on a drug that, while active, appears to be inferior to the standard of care in psoriasis, Cowen & Co analyst Eric Schmidt wrote in a note. The drug’s profile compares poorly to Celegene Corp’s Otezla, which was approved last year for psoriasis, and Biogen Inc’s